Refractory Leukemia
Showing 1 - 25 of >10,000
Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted
Recruiting
- Acute Myeloid Leukemia
- +3 more
- CD123 targeted CAR-NK cells
-
Taiyuan, Shanxi, ChinaShanxi Bethune Hospital
Aug 28, 2023
Recurrent Leukemia, Refractory Leukemia Trial in Houston (Decitabine, Tegavivint)
Recruiting
- Recurrent Leukemia
- Refractory Leukemia
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma Trial in Shanghai (BCL2 Inhibitor plus IM2 regimen)
Recruiting
- T-lymphoblastic Lymphoma
- +5 more
- BCL2 Inhibitor plus IM2 regimen
-
Shanghai, Shanghai, ChinaShanghai General hospital,Shanghai Jiao Tong University School o
Jan 10, 2023
Refractory Leukemia Trial in Shanghai (CALGE-VEN- RIC-MBF)
Recruiting
- Refractory Leukemia
- CALGE-VEN- RIC-MBF
-
Shanghai, Shanghai, China
- +2 more
May 22, 2023
Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia Trial
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- +7 more
- Anti-CD123 ADC IMGN632
- +7 more
- (no location specified)
Dec 28, 2022
Refractory Leukemia, Relapsed Leukemia, Acute Myelogenous Leukemia Trial in Miami (STING-Dependent Activators (STAVs) Loaded
Not yet recruiting
- Refractory Leukemia
- +4 more
- STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells
- Dendritic Cell Vaccine
-
Miami, FloridaUniversity of Miami
Jan 23, 2023
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse
- anti Tim-3/CD123 CAR-T cell therapy
-
Xuzhou, Jiangsu, ChinaKailin Xu
Nov 4, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- (no location specified)
Nov 9, 2023
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphoblastic Leukemia With Failed Remission
-
São Paulo, SP, BrazilInstituto do Cancer do Estado de Sao Paulo
Sep 12, 2023
Acute Leukemia, Recurrent Leukemia, Refractory Leukemia Trial in Columbus (Best Practice, Bright White Light Therapy, Survey
Recruiting
- Acute Leukemia
- +2 more
- Best Practice
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 14, 2022
Relapsed/Refractory Chronic Lymphocytic Leukemia Trial in Tianjin (GNC-035)
Not yet recruiting
- Relapsed/Refractory Chronic Lymphocytic Leukemia
-
Tianjin, Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital, Chinese Aca
Jul 13, 2023
Acute Myeloid Leukemia Trial in Beijing (Ven+CAG)
Recruiting
- Acute Myeloid Leukemia
-
Beijing, Beijing, ChinaPeking University People's Hospital
Jun 23, 2023
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small
Recruiting
- Relapsed or Refractory CD19+ B-cell Lymphoma
- +2 more
- TBI-2001
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 26, 2023
Acute Myeloid Leukemia Refractory Trial in Lyon (NP137, Azacitidine Injection, Venetoclax)
Recruiting
- Acute Myeloid Leukemia Refractory
- NP137
- +2 more
-
Lyon, FranceCentre Léon Bérard
Nov 30, 2023
Refractory B-cell Acute Lymphoblastic Leukemia Trial in Houston (Mosunetuzumab)
Not yet recruiting
- Refractory B-cell Acute Lymphoblastic Leukemia
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2023
B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- HY004
- +2 more
- (no location specified)
Aug 18, 2023
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)
Not yet recruiting
- T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- CD7-CART01
- (no location specified)
Sep 26, 2023
Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (UAE Inhibitor TAK-243)
Not yet recruiting
- Myelodysplastic Syndrome
- +4 more
- UAE Inhibitor TAK-243
- (no location specified)
Oct 20, 2022
B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- (no location specified)
Oct 10, 2023
Leukemia, Lymphoma Trial in United States (SCRI-CAR22v2)
Recruiting
- Leukemia
- Lymphoma
- SCRI-CAR22v2
-
Los Angeles, California
- +4 more
Jan 18, 2023
Relapsed/Refractory Acute Myeloid Leukemia Trial in Hangzhou (B7-H3 target, CAR gene modified gdT cell injection)
Recruiting
- Relapsed/Refractory Acute Myeloid Leukemia
- B7-H3 target, CAR gene modified gdT cell injection
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Zhejiang University School of Med
Feb 15, 2023
Relapsed and/or Refractory Multiple Myeloma, Plasma Cell Leukemia in Relapse Trial in Shanghai (Biological)
Recruiting
- Relapsed and/or Refractory Multiple Myeloma
- Plasma Cell Leukemia in Relapse
- Biological
-
Shanghai, Shanghai, ChinaShanghai Tongji Hospital
May 29, 2023
B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- QH103 Cell Injection
- +2 more
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Sep 21, 2023
B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)
Not yet recruiting
- B Precursor Acute Lymphoblastic Leukemia
- Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
- (no location specified)
Sep 25, 2023